Application
Fig1: Western blot analysis of EIF5 on human EIF5 recombinant protein using anti-EIF5 antibody at 1/1,000 dilution.Application
Fig2: Western blot analysis of EIF5 on HEK293 (1) and EIF5-hIgGFc transfected HEK293 (2) cell lysate using anti-EIF5 antibody at 1/1,000 dilution.Application
Fig3: ICC staining EIF5 (green) and Actin filaments (red) in Hela cells. The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.Application
Fig4:Immunohistochemical analysis of paraffin-embedded human bladder cancer tissue using anti-EIF5 antibody. Counter stained with hematoxylin.Application
Fig5: Immunohistochemical analysis of paraffin-embedded human rectum cancer tissue using anti-EIF5 antibody. Counter stained with hematoxylin.Application
Fig6:Flow cytometric analysis of Hela cells with EIF5 antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).| Product Name | EIF5 [H6-D11] |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | 2810011H21Rik antibody D12Ertd549e antibody EIF 5 antibody EIF 5A antibody eIF-5 antibody Eif5 antibody Eukaryotic initiation factor 5 antibody Eukaryotic translation initiation factor 5 antibody IF5_HUMAN antibody MGC36374 antibody MGC36509 antibody |
| Product description | In mammalian cells, translation is controlled at the level of polypeptide chain initiation by initiation factors. The eukaryotic translation initiation factor 5 (eIF5) catalyzes the hydrolysis of GTP bound to the 40S ribosomal subunit, a function necessary for the subsequent joining of the 40S and 60S subunits to form the 80S initiation complex. eIF-4E specifically binds to the mRNA cap to promote unwinding and exposure of the AUG-initiation codon. Overexpression of eIF-4E can lead to cell transformation and tumorigenesis. An additional initiation factor, eIF-2, is present as a heterotrimer composed of eIF-2a, eIF-2b and eIF-2g subunits. This heterotrimer forms a complex with GTP and tRNA which then binds to the 40S ribosomal subunit. After the formation of the 80S initiation complex, eIF-2 is hydrolyzed and eIF-2-GDP is released from the complex. eIF-2-GDP is subsequently converted to eIF-2-GTP, a reaction catalyzed by eIF-2B, and is then available to catalyze another round of initiation. |
| Immunogen | Recombinant protein |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG2a |
| Host Species | Mouse |
| Tested Applications | WBICCIHCFC |
| WB:1:500-1:2,000 ICC:1:50-1:200 IHC:1:50-1:200 FC:1:50-1:200 |
|
| Species Reactivity | Human |
| Concentration | 2mg/ml |
| Alternative Names | 2810011H21Rik antibody D12Ertd549e antibody EIF 5 antibody EIF 5A antibody eIF-5 antibody Eif5 antibody Eukaryotic initiation factor 5 antibody Eukaryotic translation initiation factor 5 antibody IF5_HUMAN antibody MGC36374 antibody MGC36509 antibody |
|---|---|
| Molecular Weight(MW) | 49 kDa |
| Cellular Localization | Cytoplasm. Plasma membrane |
Application
Fig1: Western blot analysis of EIF5 on human EIF5 recombinant protein using anti-EIF5 antibody at 1/1,000 dilution.
Application
Fig2: Western blot analysis of EIF5 on HEK293 (1) and EIF5-hIgGFc transfected HEK293 (2) cell lysate using anti-EIF5 antibody at 1/1,000 dilution.
Application
Fig3: ICC staining EIF5 (green) and Actin filaments (red) in Hela cells. The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Application
Fig4:Immunohistochemical analysis of paraffin-embedded human bladder cancer tissue using anti-EIF5 antibody. Counter stained with hematoxylin.
Application
Fig5: Immunohistochemical analysis of paraffin-embedded human rectum cancer tissue using anti-EIF5 antibody. Counter stained with hematoxylin.
Application
Fig6:Flow cytometric analysis of Hela cells with EIF5 antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).| Positive Control | Human EIF5 recombinant protein, EIF5-hIgGFc transfected HEK293 cell lysate, Hela, human bladder cancer, human rectum cancer |
|---|---|
| Application Notes | WB:1:500-1:2,000 ICC:1:50-1:200 IHC:1:50-1:200 FC:1:50-1:200 |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. |
